ArticleBiomedicine & pharmacotherapy = Biomedecine & pharmacotherapie2026
Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.
Article in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. Euphol, a triterpenoid alcohol derived from Euphorbia tirucalli, has demonstrated anti-tumor activity in various cancer cell lines; however, its effects in advanced preclinical models remain underexplored. Here, we aimed to investigate the biological and chemopreventive potential of euphol across multiple colorectal experimental systems. Euphol exposure significantly reduced cell viability and colony formation in a dose-dependent manner in a panel of commercial and primary CRC cell lines. In 3D mouse-derived organoids (MDOs), euphol decreased organoid viability while preserving immune cell populations (CD4 +, CD8 +, NK) in co-culture with murine splenocytes. Immunoblotting revealed no modulation of PKC isoforms phosphorylation. In vivo, euphol suppressed intestinal tumor development in the Apc
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.